SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-307531
Filing Date
2019-12-06
Accepted
2019-12-05 21:34:02
Documents
6
Period of Report
2019-12-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d832904d8k.htm 8-K 19271
2 EX-99.1 d832904dex991.htm EX-99.1 18673
3 GRAPHIC g832904dsp0001.jpg GRAPHIC 2186
4 GRAPHIC g832904dsp0001a.jpg GRAPHIC 2918
5 GRAPHIC g832904dsp0001b.jpg GRAPHIC 2207
6 GRAPHIC g832904dsp0005.jpg GRAPHIC 3459
  Complete submission text file 0001193125-19-307531.txt   54652
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 191271620
SIC: 2834 Pharmaceutical Preparations